

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—Consortium Management Group, Inc. on Behalf of Medical Countermeasure Systems Consortium

Notice is hereby given that, on December 8, 2015, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), Consortium Management Group, Inc. on behalf of Medical Countermeasure Systems Consortium (“CMG–MCSC”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing (1) the identities of the parties to the venture and (2) the nature and objectives of the venture. The notifications were filed for the purpose of invoking the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances.

Pursuant to Section 6(b) of the Act, the identities of the parties to the venture are: Consortium Management Group, Inc. on behalf of Medical Countermeasure Systems Consortium, Washington, DC; ABL, Inc., Rockville, MD; Altimmune, Inc., Gaithersburg, MD; AEQUOR, Inc., Oceanside, CA; Appili Therapeutics, Inc., Halifax, Nova Scotia; BalinBac Therapeutics, Inc., Princeton, NJ; Battelle, Columbus, OH; Bavarian Nordic, Kvistgard, DENMARK; Chemapotheca LLC, Delamar, NY; CONTINUUS Pharmaceuticals, Inc., Woburn, MA; Creare LLC, Hanover, NH; CUBRC, Inc., Buffalo, NY; Dyne Immune Institute for Translational Medicine and Research, Wurtsboro, NY; DynPort Vaccine Company LLC, a CSC Company, Frederick, MD; Elusys Therapeutics, Inc., Pine Brook, NJ; Emergent Biosolutions Inc., Gaithersburg, MD; First Line Technology, LLC, Chantilly, VA; GenArraytion, Inc., Rockville, MD; Ginkgo Bioworks, Boston, MA; IIT Research Institute, Chicago, IL; Institute for Therapeutic Innovation, University of Florida, Orlando, FL; InvivoSciences, Inc. Madison, WI; Lovelace Biomedical and Environmental Research Institute (LBERI), Albuquerque, NM; Luminox Corporation, Austin, TX; Maurer & Hutson Consulting, Seattle, WA; MediVector, Inc., Boston, MA; Mesa Science Associates, Inc., Frederick, MD; Molecular Engineering & Sciences Institute, Seattle, WA; Murtech, Inc., Glen Burnie, MD; Nanotherapeutics, Inc., Alachua, FL; Noninvasix, Inc.,

Galveston, TX; Philips Healthcare, Andover, MA; PnuVax Incorporated, Kingston, CANADA; The Preclinical Radiobiology Laboratory, Division of Translational Radiation Sciences, Department of Radiation Oncology, University of Maryland, School of Medicine, Baltimore, MD; Quintiles, Inc., Durham, NC; Science Applications International Corporation, McLean, VA; Smart Consulting Group, West Chester, PA; Southern Research, Birmingham, AL; Southwest Research Institute, San Antonio, TX; Spero Therapeutics, Cambridge, MA; Therabron Therapeutics, Inc., Rockville, MD; Trideum Biosciences LLC, Huntsville, AL; University of Pittsburgh Center for Military Medicine Research, Pittsburgh, PA; Vaxess Technologies, Inc., Cambridge, MA; and Washington to Washington Consulting, Seattle, WA.

The general area of the CMG–MCSC’s planned activity is (a) to enter into an Other Transaction Agreement (“OTA”) with the U.S. Government (“Government”) for the funding of certain research, development, testing and evaluation of prototypes to be conducted as a collaboration between the Government and Consortium Members, to enhance the capabilities of the Government and its departments and agencies in the field of countermeasures against chemical, biological, radiological and nuclear threats; (b) to develop countermeasures, first response and resilient systems; (c) to participate in the establishment of sound technical and programmatic performance goals based on the needs and requirements of the Government’s Technology Objectives; (d) to provide a unified voice to effectively articulate the global and strategically important role medical countermeasures play in current and future national security objectives; and (e) to maximize the utilization of the Government’s and Members’ capabilities to effectively develop critical technologies which can be deployed and transitioned.

Patricia A. Brink,

Director of Civil Enforcement, Antitrust Division.

[FR Doc. 2016–01265 Filed 1–21–16; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—IMS Global Learning Consortium, Inc.

Notice is hereby given that, on December 29, 2015, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), IMS Global Learning Consortium, Inc. (“IMS Global”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Cobb County School District, Smyrna, GA; Duncanville ISD, Duncanville, TX; EdX Inc., Cambridge, MA; eSyncTraining, Irvine, CA; K12.com, Herndon, VA; Motivis Learning, Salem, NH; Otus, Highland Park, IL; and Southern New Hampshire University/College for America, Manchester, NH, have been added as parties to this venture.

Also, Saylor Foundation, Washington, DC; and Blue Canary, Chandler, AZ, have withdrawn as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and IMS Global intends to file additional written notifications disclosing all changes in membership.

On April 7, 2000, IMS Global filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on September 13, 2000 (65 FR 55283).

The last notification was filed with the Department on October 13, 2015. A notice was published in the **Federal Register** pursuant to Section 6(b) of the Act on November 10, 2015 (80 FR 69698).

Patricia A. Brink,

Director of Civil Enforcement, Antitrust Division.

[FR Doc. 2016–01251 Filed 1–21–16; 8:45 am]

BILLING CODE P